Understand treatment

Who can consider GLP-1 medication for weight management?

Understand common adult BMI criteria, the limits of a screening number, and the health review behind a GLP-1 prescribing decision.

By CoreAge Rx · Published · Updated · 4 min read

Published by CoreAge Rx. This is company-published educational and promotional content, not an independent review or third-party endorsement.

General education; individual care decisions require a licensed clinician. This article does not report a clinical review or study of CoreAge Rx patients.

The quick answer

For adult weight management, clinicians may consider medication when BMI is at least 30, or at least 27 with a weight-related health condition. These common criteria are a starting point for assessment, not an automatic prescription. The specific medicine, medical history, current treatments and individual benefits and risks still need review.

Start with the reason treatment is being considered

NIDDK describes common adult weight-management criteria as a BMI of 30 or higher, or 27 or higher with a weight-related health problem such as high blood pressure or type 2 diabetes. It also emphasizes that medication is not appropriate for everyone with a high BMI.

This article addresses adult weight-management assessment. GLP-1-related medicines can have other approved uses, and eligibility depends on the specific product and condition. Do not apply these adult thresholds to children or assume that they determine treatment for diabetes or another diagnosis.

BMI helps screen; it does not describe the whole person

BMI relates weight to height. CDC explains its limits: it does not directly measure body fat, distinguish fat from muscle and bone, or show where fat is carried. A clinical assessment can consider history, examination and other findings alongside that number.

A calculator result can therefore help you begin a conversation without being the final answer. Describe the health concern behind your interest in treatment, the changes you have already tried and what you hope care will help you do. The clinician can interpret the measurement in that context.

The medicine’s warnings still apply when a BMI threshold is met

A product’s prescribing information includes reasons it should not be used and situations requiring extra care. For example, the Zepbound label lists a personal or family history of medullary thyroid carcinoma, or multiple endocrine neoplasia syndrome type 2, among its contraindications. It also describes risks involving other medicines, including a higher risk of low blood sugar with insulin or medicines such as sulfonylureas.

These are examples of why a health review matters, not a complete screening checklist. Tell the clinician about diagnoses, allergies, pregnancy or pregnancy plans, previous medication problems, prescriptions and supplements. Do not leave out a condition because an online questionnaire or a friend’s account makes it seem unrelated.

Two similar BMI results can lead to different conversations

Consider two fictional adults with a BMI of 31. One takes insulin and needs the care team to review blood sugar management and medication interactions. The other has a family history of medullary thyroid carcinoma, which raises a contraindication question for the example product above. Their matching BMI does not make their treatment decisions equivalent.

The useful next step is to supply accurate information and understand the clinician’s reasoning. Do not change an existing medicine to make yourself appear eligible. If a treatment is unsuitable, ask which other forms of weight-management care fit your circumstances.

What this means when researching CoreAge Rx

CoreAge Rx’s medical intake instructions ask for health history, current medicines, allergies, identity verification and photos for the provider’s evaluation. The page describes clinician review and possible follow-up questions before pharmacy processing. Completing an intake form is a step in that assessment; it does not establish that a particular medication is right for you.

Use the CoreAge Rx service review to understand the service, and use our prescriber and pharmacy guide to identify the team involved. Ask who will interpret your history and how to clarify information after submitting it.

CoreAge Rx describes compounded semaglutide and tirzepatide among its offerings. FDA says compounded drugs are not approved and should be considered only when an approved drug cannot meet the patient’s medical needs. Meeting a common weight-management screening threshold does not by itself answer that separate product question. Our approval and compounding explainer covers the distinction.

Leave the assessment with a reasoned plan

Whether treatment is recommended or declined, ask what the decision means for your next steps. The aim is an appropriate care plan that you understand.

  • Which health concern and treatment goal are we addressing?
  • What in my history supports this choice, and what risks need attention?
  • Which medicine and formulation are you recommending, if any?
  • How will we review benefits, side effects and ongoing suitability?
  • If this option is unsuitable, what care or further assessment should I consider?

Common questions

Does a BMI over 30 guarantee a GLP-1 prescription?

No. It can meet a common adult weight-management screening criterion, but the clinician must still assess the specific medicine and your circumstances.

Can a website determine eligibility from height and weight alone?

Those measurements can support preliminary screening. They cannot replace the health history and clinical review needed for an individual prescribing decision.

Are these the same rules for children and teenagers?

No. This guide discusses adults. Pediatric assessment uses age-appropriate criteria and product-specific requirements with a qualified clinician.

Sources and fact-checking

Sources checked 2026-09-09. CoreAge Rx pages support descriptions of its service; medical and regulatory sources support the educational context. Offers and availability can change.

  1. NIDDK: who may benefit from weight-management medication
  2. CDC: BMI questions and limitations
  3. DailyMed: Zepbound contraindications and safety information
  4. CoreAge Rx: medical intake and provider review
  5. FDA: concerns with unapproved GLP-1 products